Medimetriks Pharmaceuticals divests US rights for Xepi one percent to Cutanea Life Sciences
6 March 2018 -

Medimetriks Pharmaceuticals Inc, an independent branded Dermatology company with integrated development capabilities and commercial operations, has divested exclusive United States rights for Xepi (ozenoxacin cream), one percent to Cutanea Life Sciences Inc, it was reported yesterday.

The deal is valued at up to USD30m, with USD29m to be paid in 2018 and the assumption of USD5m in liabilities related to Xepi.

The company retains generic rights to the product. The product is a novel bactericidal, non-fluorinated quinolone for the treatment of impetigo that Medimetriks licensed from Ferrer, a privately held Spanish pharmaceutical company, in March, 2014. Xepi was approved by the FDA in December, 2017.